Announcement PDF RNS Number : 9722T Shield Therapeutics PLC 27 July 2022 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Results of 2022 Annual General Meeting London, UK, 27 July 2022: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialization of Accrufer®/Feraccru® (ferric maltol), a novel, oral iron therapy differentiated from other conventional irons by its efficacy, well-tolerated formulation, and broad indication, announces the results of the voting for each of the resolutions as set out in the Notice of Annual General Meeting 2022. The Board reports that resolutions 1 to 10 passed as ordinary resolutions and resolutions 11 and 12 were passed as special resolutions, full details are shown below. The following table shows the votes cast on each resolution: Resolution 1 VOTES FOR 78,956,948 % VOTES AGAINST % 98.64% 1,084,971 1.36% WITHHELD VOTES 96,410 Resolution 2 78,834,489 98.56% 1,152,138 1.44% 151,702 Resolution 3 78,812,028 98.53% 1,174,599 1.47% 151,702 Resolution 4 78,848,263 98.58% 1,138,364 1.42% 151,702 Resolution 5 79,706,568 99.65% 281,098 0.35% 150,663 Resolution 6 79,694,216 99.63% 292,411 0.37% 151,702 Resolution 7 79,729,610 99.66% 270,986 0.34% 137,733 Resolution 8 79,078,603 98.80% 958,397 1.20% 101,329 Resolution 9 79,939,681 99.83% 138,207 0.17% 60,441 Resolution 10 79,744,797 99.57% 342,264 0.43% 51,268 Resolution 11 Resolution 12 79,614,031 99.48% 415,142 0.52% 109,156 78,757,527 98.41% 1,271,646 1.59% 109,156 Notes: 1. Number of shares in issue 216,192,462. 2. Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/. 3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71. For further information please contact: Shield Therapeutics plc Greg Madison, CEO Hans-Peter Rudolf, CFO Nominated Adviser and Joint Broker Peel Hunt LLP James Steel/Christopher Golden www.shieldtherapeutics.com +44 (0) 191 511 8500 +44 (0)20 7418 8900 Joint Broker finnCap Ltd Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks +44 (0)20 7220 0500 Financial PR & IR Advisor Walbrook PR Lianne Applegarth/Alice Woodings +44 (0)20 7933 8780 or shield@walbrookpr.com Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com About Accrufer®/Feraccru® Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com About Shield Therapeutics plc Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s Accrufer®/Feraccru® are registered trademarks of the Shield Group This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGDZGZNDNRGZZM